Stocks and Investing Stocks and Investing
Thu, January 16, 2025
[ 10:01 PM ] - MSN
Brookfield Corporation's SWOT analysis: stock poised for growth amid valuation gap
[ 09:41 PM ] - MSN
JPMorgan Chase chief risk officer Ashley Bacon sells $1.81 million in stock
[ 09:21 PM ] - MSN
GitLab director Karen Blasing sells shares worth $410,764
[ 06:01 PM ] - Forbes
Gold Price Today
[ 06:01 PM ] - Mining
Column: Tin falls back to earth but supply problems haven't gone away
[ 04:01 PM ] - MSN
Why Lloyds Banking Group (LYG) Is One of the Cheapest Stocks with Biggest Upside Potential?
[ 03:45 PM ] - WOPRAI
Short squeeze is starting in shares of XELA at $0 .. 825, after crossing above the $0.73 Trigger Price
[ 03:45 PM ] - WOPRAI
Short squeeze is starting in shares of HRMY at $3 .. 7, after crossing above the $37.967 Trigger Price
[ 03:21 PM ] - MSN
Despite Berkshire Selling 605,000,000 Apple Shares, Buffett Still Says It's a 'Wonderful Company'
[ 03:00 PM ] - WOPRAI
Short squeeze is starting in shares of GLCNF at $ .. 85, after crossing above the $4.589 Trigger Price
[ 03:00 PM ] - WOPRAI
Short squeeze is starting in shares of AFFL at $0 .. 07, after crossing above the $0.057 Trigger Price
[ 02:45 PM ] - WOPRAI
Short squeeze is starting in shares of HBB at $17 .. 5, after crossing above the $17.504 Trigger Price
[ 02:45 PM ] - WOPRAI
Short squeeze is starting in shares of ANGO at $1 .. 5, after crossing above the $12.622 Trigger Price
[ 02:00 PM ] - WOPRAI
Short squeeze is starting in shares of TRVN at $1 .. 91, after crossing above the $1.799 Trigger Price
[ 01:30 PM ] - WOPRAI
Short squeeze is starting in shares of PINE at $1 .. 5, after crossing above the $16.932 Trigger Price
[ 01:21 PM ] - Investopedia
Top Stock Movers Now: Morgan Stanley, KLA, UnitedHealth Group, Target, and More
[ 01:15 PM ] - WOPRAI
Short squeeze is starting in shares of CSBB at $3 .. 8, after crossing above the $37.539 Trigger Price
[ 12:45 PM ] - WOPRAI
Short squeeze is starting in shares of TURN at $3 .. 79, after crossing above the $3.789 Trigger Price
[ 12:45 PM ] - WOPRAI
Short squeeze is starting in shares of TRNO at $6 .. 2, after crossing above the $60.975 Trigger Price
[ 12:45 PM ] - WOPRAI
Short squeeze is starting in shares of TENB at $4 .. 8, after crossing above the $42.478 Trigger Price
[ 12:45 PM ] - WOPRAI
Short squeeze is starting in shares of SGDJ at $3 .. .21, after crossing above the $36.2 Trigger Price
[ 12:45 PM ] - WOPRAI
Short squeeze is starting in shares of FIHL at $1 .. 8, after crossing above the $16.766 Trigger Price
[ 12:45 PM ] - WOPRAI
Short squeeze is starting in shares of CCEL at $7 .. 502, after crossing above the $7.31 Trigger Price
[ 12:45 PM ] - WOPRAI
Short squeeze is starting in shares of AIQUF at $ .. 05, after crossing above the $162.5 Trigger Price
[ 12:41 PM ] - MSN
Fannie Mae and Freddie Mac shares drop despite Ackman's bull case
[ 12:15 PM ] - WOPRAI
Short squeeze is starting in shares of SILA at $2 .. 8, after crossing above the $24.237 Trigger Price
[ 12:15 PM ] - WOPRAI
Short squeeze is starting in shares of PHIO at $4 .. 72, after crossing above the $3.705 Trigger Price
[ 12:01 PM ] - MSN
What's Going On With Uber Stock?
[ 12:01 PM ] - Yahoo
TSMC Stock Jumps. The Nvidia Supplier's Earnings Are Boosting Other Chip Stocks Too.
[ 11:41 AM ] - MSN
Jim Cramer on Arbutus Biopharma Corporation (ABUS): 'It Loses Money'

Jim Cramer on Arbutus Biopharma Corporation (ABUS): 'It Loses Money'


Published on 2025-01-16 11:41:41 - MSN
  Print publication without navigation

  • We recently compiled a list of the Jim Cramer's Lightning Round: 7 Stocks Under the Spotlight. In this article, we are going to take a look at where Arbutus Biopharma Corporation (NASDAQ:ABUS) stands against the other stocks featured in Jim Cramer's Lightning Round.

Jim Cramer, in a recent segment, discussed Arbutus Biopharma Corporation (ABUS), a company focused on developing treatments for Hepatitis B and other coronaviruses. He highlighted that despite Arbutus's innovative approach and promising pipeline, the company is currently not profitable. Cramer pointed out that Arbutus has been incurring significant losses, which is a concern for investors looking for immediate returns. He emphasized the high-risk nature of investing in biotech firms like Arbutus, where the potential for future earnings is high, but so is the risk of failure in drug development. This analysis reflects Cramer's cautious stance on investing in companies that are not yet generating profits, especially in the volatile biotech sector.

Read the Full MSN Article at:
[ https://www.msn.com/en-us/money/top-stocks/jim-cramer-on-arbutus-biopharma-corporation-abus-it-loses-money/ar-AA1xjNei ]
Contributing Sources